secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001140361-23-051010
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive issues $45M 13.5% senior notes due 2028; redeems $34M of 12.5% notes due 2025
--------------------------------------------------------------------------------

- Issued $45M in 13.5% senior secured notes due November 1, 2028; net proceeds used to redeem $34M of existing 12.5% notes due 2025.
- Principal repayments start June 30, 2026; no revenue or cash covenants and no warrants issued.
- Royalty agreements grant note holders 1%-2% tiered royalty on net sales of Anaphylm (epinephrine sublingual film) for 8 years from first global sale.
- CEO states refinancing reduces principal and interest payments by approximately $28M through June 2025, removing near-term financial overhang.
- Morgan Stanley acted as sole placement agent; notes sold to qualified institutional buyers via private placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000114036123051010/0001140361-23-051010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000114036123051010/ef20013909_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-051010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer